Equities research analysts expect that Arbutus Biopharma Corp (NASDAQ:ABUS) will report sales of $770,000.00 for the current quarter, Zacks reports. Two analysts have made estimates for Arbutus Biopharma’s earnings. The highest sales estimate is $1.18 million and the lowest is $360,000.00. Arbutus Biopharma posted sales of $2.50 million in the same quarter last year, which suggests a negative year over year growth rate of 69.2%. The firm is expected to report its next earnings report on Wednesday, March 13th.
According to Zacks, analysts expect that Arbutus Biopharma will report full year sales of $5.04 million for the current fiscal year, with estimates ranging from $4.63 million to $5.38 million. For the next fiscal year, analysts forecast that the business will post sales of $4.24 million, with estimates ranging from $2.19 million to $7.30 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Arbutus Biopharma.
Arbutus Biopharma (NASDAQ:ABUS) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). Arbutus Biopharma had a negative net margin of 1,116.69% and a negative return on equity of 91.36%. The firm had revenue of $1.59 million during the quarter, compared to analyst estimates of $0.23 million.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Primecap Management Co. CA increased its stake in shares of Arbutus Biopharma by 1.7% during the 3rd quarter. Primecap Management Co. CA now owns 4,070,400 shares of the biopharmaceutical company’s stock valued at $38,465,000 after acquiring an additional 70,000 shares during the last quarter. Foresite Capital Management IV LLC increased its stake in shares of Arbutus Biopharma by 0.9% during the 3rd quarter. Foresite Capital Management IV LLC now owns 2,676,825 shares of the biopharmaceutical company’s stock valued at $25,296,000 after acquiring an additional 25,000 shares during the last quarter. BlackRock Inc. increased its stake in shares of Arbutus Biopharma by 1.3% during the 3rd quarter. BlackRock Inc. now owns 2,422,221 shares of the biopharmaceutical company’s stock valued at $22,891,000 after acquiring an additional 31,078 shares during the last quarter. EcoR1 Capital LLC acquired a new position in shares of Arbutus Biopharma during the 3rd quarter valued at about $11,641,000. Finally, Morgan Stanley increased its stake in shares of Arbutus Biopharma by 39.4% during the 3rd quarter. Morgan Stanley now owns 1,025,353 shares of the biopharmaceutical company’s stock valued at $9,690,000 after acquiring an additional 289,556 shares during the last quarter. 42.59% of the stock is owned by institutional investors.
ABUS stock traded down $0.15 during trading on Friday, hitting $3.54. The stock had a trading volume of 5,472 shares, compared to its average volume of 206,532. Arbutus Biopharma has a 1-year low of $3.20 and a 1-year high of $12.60. The company has a market capitalization of $204.71 million, a price-to-earnings ratio of -1.98 and a beta of 1.62. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.01.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).
Further Reading: Discover Your Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.